Multi-discipline handheld
Two wavelengths in the hand, for clinics that treat a broad caseload
Erchonia systems supplied in Australia are listed on the ARTG by the sponsor.
Device claims reference published clinical studies, not marketing copy.
Supplied to physiotherapy, podiatry and chiropractic practices nationally.
Payment is completed on the encrypted RehaCare store.
Overview
The GVL is a handheld Erchonia system pairing green and violet laser diodes in a single unit. Handheld delivery gives the practitioner positional control — useful when presentations are focal, awkwardly located, or vary session to session. For mixed caseloads where no two patients share a protocol, that flexibility matters more than fixed-position repeatability.
Two diode wavelengths in one handheld body, selected per presentation rather than fixed to a single protocol.
Handheld delivery lets the practitioner target the presentation directly, including regions a fixed emitter cannot reach comfortably.
The unit moves between treatment rooms, so it does not consume floor space in a small practice.
Certification, install support and Australian servicing through RehaCare.
How it works
Green or violet output is selected against the presentation in front of you rather than fixed to one protocol.
The handpiece is positioned directly over the treatment area, including regions a fixed emitter cannot reach comfortably.
Treatment sits inside an existing appointment alongside manual therapy and loading work — no separate booking type required.
Specifications
Clinical trial results
2
Wavelengths in one handheld
Green and violet selected per presentation.
0
Rooms required
Portable between treatment rooms and sites.
RCT
Evidence base
Placebo-controlled trial data underpins Erchonia clearances.
Evidence
Erchonia builds its indications on randomised, double-blind, multi-centre, placebo-controlled trials — the same standard applied to pharmaceutical review — so the claims you make in clinic are defensible.
Randomised, double-blind, placebo-controlled
Erchonia's clearance pathway for its low level laser platforms is built on randomised placebo-controlled trials rather than open-label case reporting.
Reported outcome. Statistically significant outcomes over placebo were reported on the primary endpoints submitted for clearance.
Controlled clinical trial
Violet laser output has been assessed in controlled trials for inflammatory dermatological presentations, with lesion counts measured against baseline.
Reported outcome. Reduction in lesion counts was reported over the treatment course with a non-thermal safety profile.
Study summaries describe the design and reported outcomes of trial work submitted by Erchonia in support of its device clearances. Full study copies and regulatory documentation are available to practitioners on request. Nothing here is patient-facing advertising or a claim of individual results.
The science
Erchonia uses low-level lasers in the visible light spectrum. The primary mechanism for absorbing visible light photons is the elevation of electrons to higher energy levels — molecular excitement.
Visible light photons match the energy volt (eV) gap between electron orbits and move the electron to an excited state. In that state, chemical reactions occur: photons strike certain atoms, an electron is pushed to a higher energy level and picked up by an electron acceptor. The electron transport chain then uses those high-energy electrons to convert ADP into ATP.
The electron transport chain is a series of four protein complexes whose redox reactions create an electrochemical gradient, producing ATP at complex 5 (ATP synthase). If there is a "kink in the hose", electron flow is limited or blocked — the laser targets the complexes to unkink it. This process does not happen with infrared lasers.
Drives complexes 1 and 2 at the entry of the electron transport chain.
The only wavelength shown to affect complex 3 — the step required to reach complex 4.
Acts on complex 4, immediately before ATP synthase produces ATP.
Does not carry the electron volts (eV) required to influence any complex.
Common misconception
One of the biggest misconceptions in laser therapy is that higher-powered lasers using longer wavelengths penetrate deeper into the body. More power meaning deeper penetration is a claim unsupported by research or clinical data — and applying that assumption without understanding the mechanism can be unsafe.
What matters is whether the photon energy matches the eV gap needed to excite electrons at a specific complex. That is a function of wavelength, not wattage.
Erchonia's 1 treatment challenge
Real-life accounts from people treated with Erchonia low-level lasers. The 1 Treatment Challenge shows what a single, properly dosed session can do — the same measure the GVL was tested against for range of motion and pain.
Find a providerHandheld series
Entry level
The original dual-diode handheld and the first cleared for chronic neck and shoulder pain. Shown to stimulate complex 4. The usual starting point for clinics new to laser therapy.
Most popular
Combines two wavelengths in a single treatment, with better study outcomes than 635nm alone, plus antibacterial and antimicrobial applications. Shown to stimulate complexes 1, 2 and 4.
Learn moreThis device
The most effective wavelength combination reported for increased range of motion and reduced pain in a single session, and the first and only green wavelength cleared for pain and inflammation. Shown to stimulate complexes 1, 2 and 3.
For optimal impact on the electron transport chain, all three wavelengths matter: violet for complexes 1 and 2, green for complex 3, and red for complex 4. To support mitochondrial function holistically, the three wavelengths work together — infrared influences none of them.
Laser vs LED
Erchonia has always used LEDs as the placebo device in its randomised, double-blind, multi-centre, placebo-controlled clinical trials, to prove the efficacy of true cold lasers over LEDs.
Don't devalue your practice with cheap, at-home LEDs. A clinic-grade laser is what separates a billable clinical intervention from a consumer gadget your patients can buy online.
Reported outcomes from randomised, double-blind, placebo-controlled trial arms, with an LED array used as the placebo device.
| LED vs laser | Red Only | Red & Violet | Green & Violet | LED (placebo group) |
|---|---|---|---|---|
| Subjects (n) | 43 | 44 | 43 | 43 |
| Duration of pain (months) | 61.7 | 76.58 | 89.19 | 82 |
| Subjects meeting study success criteria (≥ 30% pain reduction) | 65% | 75% | 81% | 11% |
| Improvement in pain, baseline to immediately after treatment | 48% | 45% | 52% | 8% |
| Improvement in range of motion (°) | 14% | 29% | 32% | 2% |
Figures as reported by Erchonia from placebo-controlled clinical trials. Individual results vary; refer to the published studies for full methodology.
Practice fit
GVL suits multi-practitioner clinics where the caseload is broad and unpredictable. If your protocols change patient to patient, a handheld unit is the practical choice over a fixed system.
Handheld delivery requires the practitioner present for the treatment window. That is a real cost against a hands-free unit if your list is tightly booked.
Device selection
Two questions narrow five systems down to the one or two worth a demonstration. This is a starting point, not a prescription — our clinical team will still walk your caseload before anything is quoted.
Choose what you treat to see a recommendation.
GVL and EVRL are close on workflow and differ on wavelength pairing. Tell us what walks through your door and we will make a specific recommendation.
Already know what you need? Browse the RehaCare store for consumables and in-stock clinical ranges.
GVL Laser enquiry
